Products
Gomiliximab Biosimilar Monoclonal Antibody (CD23) for Research
Pre-Made Gomiliximab biosimilar, Whole mAb, Anti-FCER2/CD23 Antibody: Anti-BLAST-2A/CLEC4J/FCE2/FCErII/IGEBF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lumiliximab is an IgG1k monoclonal antibody that targets CD23. It acts as an immunomodulator and was awarded orphan drug status and fast track designation by the FDA.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-250-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Gomiliximab biosimilar, Whole mAb, Anti-FCER2/CD23 Antibody: Anti-BLAST-2A/CLEC4J/FCE2/FCErII/IGEBF therapeutic antibody |
| INN Name | Gomiliximab |
| Target | CD23 |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | 3fzu:HL:CD |
| 95-98% SI Structure | None |
| Year Proposed | 2004 |
| Year Recommended | 2004 |
| Companies | Biogen Idec |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Allergic asthma;Allergic rhinitis;Chronic lymphocytic leukaemia |
| Development Tech | na |
About target - FCER2
1. Protein Low affinity immunoglobulin epsilon Fc receptor
2. Gene FCER2
3. Organism Homo sapiens (Human)
Function
Low-affinity receptor for immunoglobulin E (IgE) and CR2/CD21. Has essential roles in the regulation of IgE production and in the differentiation of B-cells (it is a B-cell-specific antigen).
Miscellaneous
There are two kinds of Fc receptors for IgE, which differ in both structure and function: high affinity receptors on basophils and mast cells and low affinity receptors on lymphocytes and monocytes.
